Steroid tapering showdown: which method wins for RA patients?
NCT ID NCT07227428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two strategies for slowly reducing prednisolone (a steroid) in people with stable rheumatoid arthritis. One method splits a 5 mg tablet into halves, the other reduces by 1 mg at a time. Over six months, 206 participants will be followed to see which approach keeps disease activity low while successfully stopping steroids. The goal is to create a safer, evidence-based tapering plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prednisolone
What this could lead to
If successful, this could provide a clear, safer method for reducing long-term steroid use in rheumatoid arthritis, lowering side effects like bone loss and infection risk.
What could go wrong
This is a phase 4 study with 206 participants, so results may not apply to all patients. Tapering steroids can sometimes trigger disease flares or adrenal insufficiency.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••